Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $53.17 USD
Change Today -2.65 / -4.75%
Volume 433.4K
KITE On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Open
$55.37
Previous Close
$55.82
Day High
$56.73
Day Low
$53.00
52 Week High
01/15/15 - $89.21
52 Week Low
09/8/14 - $23.85
Market Cap
2.3B
Average Volume 10 Days
1.0M
EPS TTM
$-1.41
Shares Outstanding
43.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. It has research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; and collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

116 Employees
Last Reported Date: 08/10/15
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $387.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $502.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $218.8K
Vice President of Product Sciences
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

kite pharma inc (KITE) Key Developments

Kite Pharma Provides Update on KTE-C19 Clinical Trial

Kite Pharma, Inc. provided an update from the company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. In May, Kite announced that the first patient was treated with KTE-C19 in the Phase 1 portion of the trial and have since treated multiple patients. Complete responses have been observed by investigators. The responses happened shortly after treatment was administered and Kite is monitoring these patients to determine durability of treatment. To date, toxicities associated with treatment have been similar to those observed in the National Cancer Institute's study of anti-CD19 CAR T cell therapy. There was one patient death early in the study, which was determined to be unrelated to KTE-C19 by the study investigator. After appropriate discussions with the U.S. Food and Drug Administration (FDA), Kite continued to enroll and treat patients in its study and the study was never placed on clinical hold. Kite has submitted an abstract and plans to present top-line data from the Phase 1 portion of the trial at the upcoming 2015 American Society of Hematology (ASH) Annual Meeting, to take place in Orlando, FL, December 5-8, 2015. Kite's Phase 1/2 clinical trial of KTE-C19 is a single arm, open-label, multi-center study, designed to determine the safety and efficacy of KTE-C19 in patients with refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL). Upon completion of the Phase 1 portion of the study, Kite expects to proceed with the Phase 2 portion that will include a total of approximately 112 patients.

Kite Pharma, Inc. - Special Call

To provide a corporate update

Kite Pharma, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Kite Pharma, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported collaboration revenue of $4.4 million compared to $0 for the second quarter of 2014. The increase was primarily comprised of the amortization of deferred revenue related to the $60.0 million upfront payment received from Amgen in the first quarter of 2015. Loss from operations was $21,959,000 compared to $11,140,000 a year ago. Net loss was $20,892,000 compared to $17,890,000 a year ago. Basic and diluted net loss per share was $0.48 compared to $2.27 a year ago. Net loss attributable to common stockholders – Non-GAAP was $11,511,000 compared to $10,846,000 a year ago. Basic and diluted net loss per share attributable to common stockholders – Non-GAAP was $0.26 compared to $1.38 a year ago. For the six months, the company reported collaboration revenue of $7,284,000. Loss from operations was $37,510,000 compared to $14,302,000 a year ago. Net loss was $35,979,000 compared to $20,499,000 a year ago. Basic and diluted net loss per share was $0.84 compared to $3.20 a year ago. Net loss attributable to common stockholders – Non-GAAP was $19,921,000 compared to $14,347,000 a year ago. Basic and diluted net loss per share attributable to common stockholders – Non-GAAP was $0.47 compared to $2.13 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $53.17 USD -2.65

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies
 

Industry Analysis

KITE

Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 331.4x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 281.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit www.kitepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.